{"filings":[{"id":1304077,"accession_number":"0001040130-26-000027","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2026-06-26T20:10:26+00:00","items":["5.02","9.01"],"status":"ready","headline":"PetMed director Leah Solivan not standing for reelection at Aug 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leah A. Solivan informed PetMed Express she will not stand for reelection at the 2026 annual meeting on August 11, 2026.","Ms. Solivan will continue as director until the August 11, 2026 annual meeting.","Her decision was not due to any disagreement with the Company or Board on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":806238,"accession_number":"0001040130-26-000016","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2026-06-02T20:15:54+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $42.8M (down 15.6% YoY); FY net sales $179M (down 21.1%) on lower prescription sales.","Q4 net loss narrowed to $4.1M ($0.19/sh) from $11.6M; FY net loss widened to $57.3M ($2.74/sh) from $6.3M.","FY adjusted EBITDA -$15.4M (vs +$0.7M) due to $26.7M goodwill impairment and $4.5M severance/investigation.","Board evaluated unsolicited buyout proposals at $4.00-$4.25/sh but opted not to pursue; open to future offers.","Management cites sequential QoQ sales uptick, cost reductions, and B2B expansion (Rural King fulfillment deal)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583197,"accession_number":"0001040130-26-000010","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2026-05-21T20:40:56+00:00","items":["5.08"],"status":"ready","headline":"PetMed Express sets 2026 Annual Meeting for Aug 11, 2026; shareholder proposal deadline May 31","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2026 Annual Meeting will be held virtually on August 11, 2026.","New deadlines apply because meeting date is more than 30 days from 2025 Annual Meeting.","Deadline for Rule 14a-8 shareholder proposals and proxy access nominations: May 31, 2026.","Deadline for other proposals and director nominations outside Rule 14a-8: also May 31, 2026.","Shareholders must comply with Bylaws and Exchange Act requirements for submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100553,"accession_number":"0001040130-26-000002","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PetMed Express stockholders elect 5 directors, back executive pay, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Batushansky, Campbell, LaCamp, Mennen, Solivan; for votes 6.9M-7.3M, against 2.9M-3.5M.","Advisory vote on executive compensation approved: 8.53M for, 1.79M against, 82k abstentions.","Ratification of Baker Tilly as independent auditor for FY2026 passed: 14.98M for, 0.45M against, 79k abstentions.","Broker non-votes of 5.1M shares on director elections and say-on-pay (non-routine items).","15.5M shares represented out of 21.4M outstanding; quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116870,"accession_number":"0001040130-25-000112","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K/A","filed_at":"2025-12-29T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"PetMed Express amends 8-K: RSM dismissal effective Dec 19; Baker Tilly appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissal of RSM US LLP effective December 19, 2025, after completing interim reviews for June and Sep 2025 quarters.","No adverse opinions, disagreements, or reportable events with RSM during fiscal years ended March 2024 and 2025.","Baker Tilly US, LLP engaged as new auditor for fiscal year ending March 31, 2026, starting with Dec 2025 quarter review.","No consultations with Baker Tilly on accounting matters prior to engagement; letter from RSM filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116876,"accession_number":"0001040130-25-000097","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"PetMed Express dismisses RSM as auditor, hires Baker Tilly; cites material weaknesses in controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed RSM US LLP as independent auditor effective after interim reviews; Baker Tilly US LLP engaged for FY2026.","No disagreements on accounting principles but multiple reportable events: material weaknesses in ITGC, tone at the top, revenue recognition, and restatements.","Material weaknesses include inadequate control environment, ineffective whistleblower process, and prior Audit Committee chair’s failure to report complaints to RSM.","Former audit reports for FY2024 and FY2025 were unqualified; material weaknesses not fully remediated as of filing date.","Company does not expect auditor change to delay filing of Q1 and Q2 FY2026 Form 10-Qs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116875,"accession_number":"0001040130-25-000091","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","3.03","5.02","8.01","9.01"],"status":"ready","headline":"PetMed Express extends shareholder rights plan to December 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan expiration extended from December 2, 2025 to December 2, 2026.","Board states shares do not reflect intrinsic value; recent accumulation by certain shareholders.","Plan designed to ensure fair treatment and prevent inadequate takeover bids.","Interim CFO Douglas Krulik salary increased to $330K; new change-of-control severance agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116874,"accession_number":"0001040130-25-000086","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"PetMed Express warns Q2 net sales down ~25% YoY; receives Nasdaq delisting notice","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 net sales estimated at $43.4M-$44.5M vs $58.0M (restated) prior year.","Six-month net sales estimated at $94.5M-$95.6M vs $124.3M (restated) prior year.","Cannot estimate operating income due to pending goodwill impairment analysis.","Cash $36.1M, no debt as of September 30, 2025.","Nasdaq non-compliance for late Q1 and Q2 10-Qs; compliance plan update due by Nov 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":95544000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116873,"accession_number":"0001040130-25-000077","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints James LaCamp to board and audit committee chair; formalizes interim CEO terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James LaCamp, former Deloitte partner and current CFO of Skydio, appointed to board effective Oct 19, 2025.","LaCamp will serve as Audit Committee Chair beginning Oct 30, 2025; qualifies as audit committee financial expert.","Interim CEO Leslie Campbell entered employment agreement with $1.3M annual salary, at-will, one-year term through Aug 10, 2026.","Board now comprises six directors, five independent; four new directors added since fiscal 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116872,"accession_number":"0001040130-25-000074","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express FY2025 net sales $227M, net loss $6.3M; Q1/Q2 filings delayed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $227.0M for FY2025 below preliminary range of $231.6M-$233.6M due to restatement of promotional sales reimbursements to cost of sales.","Net loss of $6.3M widened from preliminary estimated loss of $4.5M-$5.0M, driven by a $1.2M non-cash impairment charge for intangible assets.","Cash balance of $54.7M and no debt as of March 31, 2025.","Company filed Form 10-K; plans to file Q1 and Q2 2025 reports and resume normal quarterly earnings call cadence."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":95544000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116871,"accession_number":"0001040130-25-000064","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["2.06","4.02","8.01"],"status":"ready","headline":"PetMed Express to restate FY2024, FY2023; investigation reveals revenue errors, former CEO/CFO out","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net sales overstated by ~$7.0M in FY2024 and ~$9.0M in FY2023 due to vendor payment misclassification; no net income impact.","Investigation found Dec and Mar accelerated shipments: $133k and $1.1M revenue in wrong periods; $50 coupon and nepotism issues.","Former CEO Sandra Campos, former CFO Robyn D'Elia, former Audit Chair Diana Purcel resigned; Board adopted remediation plan.","Company expects to file FY2025 10-K by mid-October 2025; material weaknesses in internal controls to be reported.","Also recorded $1.2M non-cash impairment of PCRX trade name; possible additional goodwill impairment due to stock decline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133321,"accession_number":"0001040130-25-000059","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"PetMed Express sets interim CEO salary at $550k, awards restricted shares to CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leslie C.G. Campbell, Interim CEO since Aug 11, 2025, receives $550,000 annual base salary.","Douglas Krulik (Chief Accounting Officer) granted 10,000 restricted shares, vesting in 6 months.","Campbell's salary is effective until a formal employment agreement is signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133320,"accession_number":"0001040130-25-000051","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"PetMed Express receives Nasdaq non-compliance notice; plan due Sept 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified PetMed for late filing of FY2025 10-K and Q1 FY2026 10-Q, violating Listing Rule 5250(c)(1).","Company must submit compliance plan by September 1, 2025; Nasdaq may grant exception until December 29, 2025.","Notice does not immediately affect listing of PETS common stock on Nasdaq.","Company states it is working diligently to complete and file the overdue reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133319,"accession_number":"0001040130-25-000049","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"PetMed CEO and CFO resign effective immediately; interim leaders appointed; audit investigation ongoing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Sandra Campos and CFO Robyn D'Elia resigned Aug 11, 2025; severance includes 13-month salary continuation and accelerated RSU vesting.","Board Chair Leslie Campbell named Interim CEO; CAO Doug Krulik named Interim Principal Financial Officer.","Audit Committee investigation into revenue recognition timing and coupon promotion KPIs is ongoing; no completion timeline provided.","Board reduced from 6 to 5 directors; search for permanent CEO and CFO initiated.","Campbell steps down from Audit and Compensation committees; Mennen becomes Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133318,"accession_number":"0001040130-25-000043","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Diana Garvis Purcel resigns from PetMed Board; board size reduced to six","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diana Garvis Purcel resigned effective July 24, 2025 as Board member and Audit Committee Chair.","Purcel stated no disagreement with company operating policies or practices.","Board reduced size from 7 to 6 directors effective immediately upon resignation.","Leslie C.G. Campbell appointed to fill Audit Committee role and as Chair of Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133317,"accession_number":"0001040130-25-000040","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"PetMed Express receives Nasdaq deficiency notice for late FY2025 10-K filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 2, 2025 for non-compliance with Listing Rule 5250(c)(1) due to delayed annual report.","Must submit compliance plan by September 1, 2025; Nasdaq may grant exception until December 29, 2025.","Notice has no immediate effect on trading; company previously filed a Form 12b-25 on June 16, 2025.","Company is working to complete financial statements and file Form 10-K as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133316,"accession_number":"0001040130-25-000036","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PetMed Express delays FY2025 10-K; Audit Committee probes whistleblower reports on revenue recognition","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["10-K filing delayed beyond July 1 extension; Audit Committee investigating anonymous whistleblower reports.","Reports focus on timing of revenue recognition for Q4 autoship orders and a $50 coupon promotion's effect on new customer KPIs.","Investigation ongoing with external legal counsel; no conclusions yet; company does not expect material impact on preliminary results.","Company working to file 10-K as soon as practicable; no definitive timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149975,"accession_number":"0001040130-25-000034","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express prelim Q4 sales $51-53M vs $66.5M; net loss widens to $10M; delays 10-K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales estimated $51.1-53.1M (down ~21% YoY); net loss $9.9-10.4M vs $5.0M prior year.","FY2025 net sales $231.6-233.6M (down ~17% YoY); FY net loss $4.5-5.0M vs $7.5M prior year.","FY net loss includes $8.7M non-cash benefit from executive departure and $6.4M deferred tax asset valuation allowance.","Cash position $54.7M with no debt as of March 31, 2025.","Company filed Form 12b-25; expects to file annual 10-K by July 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149974,"accession_number":"0001040130-25-000016","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints Peter Batushansky to Board; Dr. Fulgoni to retire at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Batushansky, former CEO of Allivet and current partner at L2 Capital Partners, joins board effective April 9, 2025.","Batushansky will serve on Audit Committee and Corporate Governance and Nominating Committee; board expands from 6 to 7 members.","Dr. Gian Fulgoni, longtime board member and former Chairman, will retire when his term expires at the 2025 annual shareholders' meeting.","This is the third independent director added since 2024; company highlights ongoing board refreshment and transformation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168994,"accession_number":"0001040130-25-000012","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express Q3 net sales $53M; Adj. EBITDA rises to $2M from $0.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $53.0 million in Q3 fiscal 2025.","Gross margin rate 28.1%, up 80 bps from prior year.","Adjusted EBITDA $2.0 million vs. $0.9 million prior year, a $1.1M improvement.","G&A expenses reduced by $2.6 million year-over-year.","CEO highlights transformation progress and operational efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":180506000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186074,"accession_number":"0001040130-24-000126","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K/A","filed_at":"2024-12-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"PetMed Express corrects executed versions of rights plan and preferred stock articles filed Dec 3","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment replaces Exhibits 3.1 and 4.1 from Dec 3 8-K with final executed copies; no disclosure changes.","Original Dec 3 filing disclosed adoption of a shareholder rights plan and creation of 100,000 shares of Series A Junior Participating Preferred Stock.","Rights agreement designates Continental Stock Transfer & Trust as rights agent.","No other amendments or new information beyond the clerical exhibit replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186076,"accession_number":"0001040130-24-000122","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"PetMed Express adopts limited-duration shareholder rights plan (poison pill) with 12.5% trigger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board cites recent significant stock accumulations by certain shareholders; stock not reflecting intrinsic value.","Rights dividend for holders of record Dec. 16, 2024; exercisable if a 12.5%+ owner is not Board-approved.","Upon trigger, non-acquiring holders can buy shares at 50% discount; rights expire Dec. 2, 2025.","Rights plan includes derivative securities in beneficial ownership definition; Board can redeem at $0.001 per right.","Plan does not prevent Board-approved transactions and allows exempt persons and existing holders to avoid trigger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186075,"accession_number":"0001040130-24-000114","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express Q2 FY2025: net sales $59.6M, net income $2.3M, EPS $0.11","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales of $59.6M; net income $2.3M ($0.11 diluted EPS) vs $0.7M ($0.03) in prior year.","Gross margin 29.1% (+0.8% YoY); Adjusted EBITDA $2.1M, sequential improvement from $(1.5)M in Q1.","CEO cites cost savings from consolidating PetMeds/PetCareRx ops; positioned for growth initiatives."],"consensus_eps_estimate":-0.0714,"consensus_eps_actual":0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":127522000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202689,"accession_number":"0001040130-24-000110","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PetMed Express adopts 2024 Inducement Incentive Plan, grants RSUs to CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan reserves 350,000 shares for equity awards to new employees as employment inducements under Nasdaq Rule 5635(c)(4).","Plan permits nonstatutory stock options, restricted stock, RSUs, and performance stock awards.","RSU grant awarded to CFO Robyn D'Elia on September 27, 2024 under the new plan.","Plan adopted without stockholder approval; terms similar to 2024 Omnibus Incentive Plan but no incentive stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202688,"accession_number":"0001040130-24-000095","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express Appoints Robyn D'Elia as Chief Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robyn D'Elia appointed CFO effective September 16, 2024; reports to CEO Sandra Campos.","D'Elia brings 25+ years of finance leadership, including CFO roles at Bed Bath & Beyond (2018-2020) and Odeko (2022-2024).","Employment agreement: 3-year term; base salary $425,000; target annual bonus 75% (max 150%) of base salary.","Initial RSU grant of $1,000,000 divided by reference price (higher of closing price or $4.00), vesting over 3 years.","Press release issued September 12, 2024 announcing the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202687,"accession_number":"0001040130-24-000081","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"PetMed Express shareholders approve 850K-share 2024 Omnibus Incentive Plan; director comp amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2024 Omnibus Incentive Plan reserving 850,000 shares (plus prior plan shares) for equity grants.","Board amended non-employee director comp program; annual RSU awards now under the Plan; total director comp capped at $750,000 per fiscal year.","All six director nominees (Campbell, Campos, Fulgoni, Mennen, Purcel, Solivan) elected with majority support; broker non-votes ~4.7M each.","Advisory say-on-pay passed with ~10.1M for vs 0.9M against; ratification of RMS US LLP as auditor passed with ~15.3M for.","Annual meeting held Aug 8, 2024; 15.7M shares voted of 20.6M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202686,"accession_number":"0001040130-24-000065","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express Q1 net income $3.8M on $8.7M stock comp reversal; sales down 13%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $68M, down 13% YoY; net income $3.8M ($0.18 diluted) vs loss of $(1.1M) ($(0.06)) prior year.","Net income increase driven by $8.7M reversal of stock compensation expense from former CEO departure.","Adjusted EBITDA $(1.5M), $4.9M lower than prior year, due to lower sales and gross profit.","New CEO Sandra Campos, plus CMO, COO, CDTO appointed; cost reduction and operational streamlining underway.","Management sees Q1 as transition quarter; early positive indicators from customer growth strategies."],"consensus_eps_estimate":-0.0459,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":67952000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202685,"accession_number":"0001040130-24-000062","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints Doug Krulik as Chief Accounting Officer, effective Aug 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doug Krulik named CAO, effective August 19, 2024, a newly created role overseeing accounting, reporting, treasury, tax, compliance, and internal controls.","Krulik brings over 20 years of finance experience; most recently VP Finance & Controller at Etherio Holdings; previously at Jushi Holdings and Magic Leap.","Base salary of $300,000, initial RSU award of 40,000 units vesting over three years, and severance of six months' base salary in certain terminations.","Krulik will report directly to the Office of the CFO and work to improve accounting operations and internal controls.","CEO Sandra Campos cited Krulik's deep expertise as key to enhancing operational excellence and financial governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218846,"accession_number":"0001040130-24-000048","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints Leah Solivan to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leah Solivan, founder of TaskRabbit and Managing Director at Fuel Capital, appointed as director effective June 24, 2024.","Will serve on Compensation and Human Capital Committee and Corporate Governance and Nominating Committee.","Solivan brings over 20 years experience building and scaling digital consumer brands.","Appointment is for term until 2024 annual meeting or successor elected; standard director compensation applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218845,"accession_number":"0001040130-24-000043","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express Q4 net loss widens to $5.0M; FY net loss $7.5M vs prior year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $66.5M (+6.6% YoY) driven by PetCareRx acquisition; legacy PetMeds sales declined.","Q4 net loss $5.0M ($0.25 diluted EPS) vs loss $0.2M ($0.01) in prior year quarter.","FY 2024 net loss $7.5M ($0.37 diluted EPS) vs net income $5.1M ($0.25) in FY 2023.","Adjusted EBITDA Q4 $0.5M (from $3.6M); FY $8.2M (from $19.8M) as G&A and marketing rose.","CEO cites challenging macro environment and new Order Management System slowdown in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218844,"accession_number":"0001040130-24-000032","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PetMed Express CFO Chambers to depart after transition; accelerated vesting of equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Christine Chambers will exit after transition period ending ~5 biz days after June 30, 2024 10-Q filing (or earlier on 15 days' notice).","Mutual termination of employment agreement; Chambers remains full-time during transition.","Upon successful transition and release, unvested RSA shares (8,667), RSUs (7,832), and special RSUs (37,425) to vest.","Company has commenced search for successor CFO; Chambers will cooperate in transition.","Chambers resigns as CFO, Treasurer, Secretary at Employment Termination Date; continues restrictions under prior agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218843,"accession_number":"0001040130-24-000028","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints Justin Mennen to Board, effective June 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Mennen appointed to Board from June 3, 2024; will serve on Audit and Governance committees.","Mennen brings >25 years tech experience; former EVP/Chief Digital Officer at Rite Aid ($24B+ revenue).","Director cash retainer set at $50k ($75k Chair from FY2026) plus 7,500 RSU annual award.","CFO Christine Chambers receives 74,850 RSUs; vesting 20% Jun 30 2024, 30% Aug 31 2024, 50% Aug 31 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218842,"accession_number":"0001040130-24-000022","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express names Sandra Campos CEO; Hulett resigns with severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matt Hulett resigned as CEO, President, and director on April 29; will remain as advisor through Aug 30.","Sandra Campos, previously a board member, appointed CEO and President effective immediately; remains on board.","Campos receives $550K base salary, $120K signing bonus, target bonus 100% of base, and $2M initial RSU grant.","Hulett receives severance through Aug 30: base salary continuation, COBRA reimbursement, and accelerated vesting of 30,000 restricted shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218841,"accession_number":"0001040130-24-000020","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express Q3 net loss $2.0M; completes sales tax restatement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $65.3M, up 11% YoY, driven by PetCareRx acquisition; legacy sales declined.","Net loss $(0.10)/diluted share vs $(0.01) loss last year; Adjusted EBITDA $924K vs $2.7M.","Cash $49.4M, no debt; AutoShip & Save and PetPlus made up 52% of revenue (vs 42% a year ago).","Restatement completed; sales tax liability now $24.2M from prior $7.8M as of Mar 2023.","Company now current on all SEC filings; restatement had no impact on FY2024 revenue or cash."],"consensus_eps_estimate":-0.0051,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":274095000.0,"consensus_period":"2024-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238752,"accession_number":"0001040130-24-000010","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"PetMed Express receives Nasdaq deficiency notice for delayed Q3 filing due to restatement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Feb 13, 2024 for non-compliance with Listing Rule 5250(c)(1) due to late Form 10-Q (quarter ended Dec 31, 2023).","No immediate impact on listing; company must submit compliance plan within 60 days; possible extension to Aug 7, 2024.","Delay stems from restatement disclosed in Feb 8, 2024 8-K; company working to file Form 10-Q as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238751,"accession_number":"0001040130-24-000004","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","4.02","7.01","9.01"],"status":"ready","headline":"PetMeds restates FY2021-2023 financials, preliminary Q3 sales up 11% YoY to $65.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement covers FY2021-2023 and Q1/Q2 FY2024 due to sales tax and deferred tax errors.","Preliminary Q3 net sales $65.3M (+11% YoY); gross margin 27.4% vs 25.9% prior year.","Sales tax liability expected $14-20M as of Mar.2020, $16-23M as of Mar.2023; FY2023 G&A decrease $6-8M.","Deferred tax asset from PetCareRx acquisition to be restated: increase goodwill, decrease deferred tax asset.","Q3 10-Q filing delayed; no impact on FY2024 revenue, COGS, or cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238750,"accession_number":"0001040130-24-000002","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"PetMed Express appoints Leslie C. G. Campbell as Chairman of the Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective January 5, 2024, Leslie C. G. Campbell succeeds Gian Fulgoni as Chairman.","Dr. Fulgoni remains on the Board and continues as chair of the Governance & Nominating Committee.","Campbell has been a director since 2018, chairs Compensation, and serves on Audit and Governance committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256239,"accession_number":"0001040130-23-000078","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express Q2 net loss of $70k; suspends quarterly dividend to invest in growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $71.0M (+9% YoY); net loss $70k vs $2.6M income; diluted EPS ($0.00) vs $0.13.","Adjusted EBITDA $3.2M, down 55% from $7.1M, citing acquisition costs and strategic investments.","Board suspends quarterly dividend, shifting capital allocation to organic and inorganic growth initiatives.","New customers up 25% YoY; AutoShip & Save and PetPlus programs account for 51% of revenue, up from 39%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":149243000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273646,"accession_number":"0001040130-23-000062","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PetMed Express annual meeting results: all director nominees elected, advisory votes approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Leslie Campbell, Sandra Campos, Gian Fulgoni, Mathew Hulett, Diana Purcel (11.4M-12.4M votes for each).","Advisory vote on executive compensation approved (11.18M for, 1.04M against, 0.48M abstain).","Shareholders recommended one-year frequency for future say-on-pay votes (12.33M for 1-year, 4.28M broker non-votes).","Ratification of RMS US LLP as auditor for fiscal 2024 passed with 16.76M for, 0.15M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273645,"accession_number":"0001040130-23-000049","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PetMed Express Q1 net sales $78.2M (+11.5% YoY); net loss $(0.9)M; declares $0.30 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $78.2M, up 11.5% YoY from $70.2M; net loss $(0.9)M ($0.04 diluted loss) vs net income $2.8M ($0.14 EPS) in prior year.","Adjusted EBITDA $3.3M, down 47% from $6.3M; new customers up 25% YoY (third consecutive quarter).","Board declared quarterly dividend $0.30/share, payable Aug 18, 2023 to holders of record Aug 14, 2023.","Acquisition of PetCareRx closed Apr 3, 2023; contributed almost full quarter of consolidated results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":78244000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290654,"accession_number":"0001040130-23-000040","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PetMed Express amends equity plans to add RSUs/PSUs, grants 19,750 equity awards to CFO, adopts AIP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended 2022 Employee Plan to add RSUs and PSUs; similarly amended 2015 Outside Director Plan to add RSUs.","CFO Christine Chambers received 11,750 RSUs (3-year graded vesting) and 8,000 PSUs tied to TSR vs S&P 600 Specialty Retail index over FY2024-2026.","Annual Incentive Plan adopted for CEO and CFO; FY2024 target: 100% CEO/50% CFO base salary, weighted 40% revenue, 60% adjusted EBITDA.","Maximum shares available under employee plan remains 1,000,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290653,"accession_number":"0001040130-23-000036","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Q4 sales $62.4M (-5% YoY), net loss $5.1M; acquires PetCareRx, declares $0.30 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $62.4M (-5% YoY); net loss $5.1M ($0.25 loss per share) vs net income $6.1M last year.","Accrued $6.9M sales tax liability; adjusted EBITDA $3.6M vs $9.5M prior year.","New customers up 12% YoY to ~72,000; Autoship & Save revenue 44% of sales (vs 31% last year).","Completed PetCareRx acquisition for $36M cash; expects it to be accretive by end of fiscal year.","Declared $0.30 per share cash dividend payable in June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":247569000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290652,"accession_number":"0001040130-23-000027","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PetMed Express Q4 net loss $5.1M, revenue down 5.4%; declares $0.30 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $(5.1)M ($0.25 diluted EPS) vs net income $6.1M ($0.30) prior year.","Q4 net sales $62.4M, down 5.4% YoY; full-year sales $256.9M, down 6.1%.","Q4 Adjusted EBITDA $3.6M, down 61.8% from $9.5M; FY adj EBITDA $19.8M down 41.9%.","New customers increased 12% YoY for Q4; AutoShip & Save recurring revenue 44% of total.","Board declared $0.30/share quarterly dividend, payable June 12, record June 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":247569000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290651,"accession_number":"0001040130-23-000023","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints Sandra Y. Campos as independent director; Jodi Watson to leave board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Campos appointed effective May 17, 2023; will serve on Governance, Audit and Compensation committees.","Campos brings experience from DVF, Global Brands Group, and serial entrepreneurship; also on Big Lots board.","Jodi Watson will not stand for re-election at August 3, 2023 annual meeting, no disagreement cited.","Board size increased to 7 temporarily with Campos, then reduced to 6 after Watson's departure.","Campos receives pro-rata restricted stock grant of 1,623 shares and cash retainer of $8,658."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290650,"accession_number":"0001040130-23-000020","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PetMed Express closes $36M all-cash acquisition of PetCareRx","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration of approx $36M in all-cash transaction.","Adds about 10,000 incremental pet food, diet and wellness products.","Expands PetMeds' addressable market from pet medication to broader healthcare.","PetCareRx brand and e-commerce operation will continue to run separately.","CapM Advisors acted as financial advisor to PetMeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311523,"accession_number":"0001040130-23-000015","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express holds Q3 FY2023 earnings call; no financial details in provided text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company held conference call on Feb 6, 2023 to discuss quarter ended Dec 31, 2022.","Transcript furnished as Exhibit 99.1 but not fully provided in this extract.","No specific revenue, EPS, or guidance figures available from the given filing text.","Forward-looking statements caution about risks including PetCareRx acquisition completion."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":187782000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311522,"accession_number":"0001040130-23-000011","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PetMed Express reports Q3 net loss of $19K; revenue down 3% to $58.9M; declares $0.30 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $58.9M (down 3% YoY); net loss $19K vs net income $4.3M prior year.","Adjusted diluted EPS $0.02; Adjusted EBITDA $2.7M, down 64% from $7.6M.","New customers increased 9% YoY, first increase in 10 quarters.","Board declares $0.30 per share quarterly dividend, payable Feb 27, 2023 to holders of record Feb 20.","Evaluating sales tax contingencies that could have material effect on results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":187782000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311521,"accession_number":"0001040130-23-000007","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PetMed Express announces definitive agreement to acquire PetCareRx","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Entered into Agreement and Plan of Merger to acquire PetCareRx, Inc.","Investor presentation furnished as Exhibit 99.1 on January 19, 2023.","Specific deal terms (price, premium, close date) not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311520,"accession_number":"0001040130-23-000003","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"PetMeds acquires PetCareRx for $36M cash; adds ~200K customers, ~$42M revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash deal $36M plus working capital adjustments; expected close Q1 2023.","PetCareRx contributed ~$42M revenue (12 mo. to Oct 2022) and ~200K customers.","Deal adds ~10K incremental wellness products; PetMeds will keep PetCareRx brand separate.","Boards of both companies approved; conditions include regulatory and pharmacy license filings.","Second major transaction in 9 months; follows Vetster investment in Apr 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330105,"accession_number":"0001040130-22-000006","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PetMed Q2 net sales $65.4M (-3% YoY), EPS $0.13 vs $0.31; dividend $0.30/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income fell to $2.6M ($0.13 diluted) from $6.3M ($0.31) a year ago; included $1.3M in non-recurring items.","Adjusted EBITDA was $7.1M, down 28% from $9.8M in Q2 FY2022.","AutoShip & Save sales grew to 39% of total sales from 34% in the prior quarter.","Board declared quarterly dividend of $0.30/share, payable Nov 30, 2022 to holders of record Nov 18.","CEO cited revenue stabilization driven by subscription growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":130544000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46653076.31390135,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-07T23:59:59+00:00|330105"}